Abstract
A set of mouse nonoclonal antibodies against the c-myc oncogene product, a 62,000 dalton nuclear binding protein involved in cell cycle control, has been constructed by immunisation with synthetic peptide fragments. One such antibody, CT14, was radiolabelled with 131I and administered to 20 patients with different malignant diseases. Good tumour localisation was observed in 12 out of 14 patients with primary bronchial carcinoma but not in patients with pulmonary metastases from primary tumours elsewhere. Successfully localised tumours were all 3 cm or more in diameter. Monoclonal antibodies against oncogene products may provide novel selective tools for the diagnosis and therapy of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Chan, S., Evan, G., Ritson, A. et al. Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product. Br J Cancer 54, 761–769 (1986). https://doi.org/10.1038/bjc.1986.238
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.238
This article is cited by
-
c-myc coded oncoprotein for immunotargeting
Cell Biophysics (1992)
-
Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents
European Journal of Nuclear Medicine (1990)